Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.20882/adicciones.1581 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cannabinoid Hyperemesis Syndrome (CHS) - An emerging gastrointestinal disorder and clinical challenge.
Dis Mon
December 2024
Director, Ellis Medical Toxicology Consulting, USA. Electronic address:
Nausea and vomiting are not uncommon symptoms resulting in emergency department (ED) or primary care visits. One of the emerging etiologies - Cannabinoid Hyperemesis Syndrome (CHS) remains significantly under-diagnosed, often resulting in unnecessary repeat ED visits and testing. This is in part due to lack of experience with and knowledge about CHS by health care professionals.
View Article and Find Full Text PDFEnhancing Cannabinoid Bioavailability in Pain Management: The Role of Cyclodextrins.
Molecules
November 2024
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.
Chronic pain (CP), including pain related to cancer, affects approximately 2 billion people worldwide, significantly diminishing quality of life and imposing socio-economic burdens. Current treatments often provide limited relief and may cause adverse effects, demanding more effective alternatives. Natural compounds from L.
View Article and Find Full Text PDFCannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against and .
Antibiotics (Basel)
October 2024
Faculty of Health, University of Canberra, Canberra, ACT 2617, Australia.
Background: Two major bacterial pathogens, and , are becoming increasingly antibiotic-resistant. Despite the urgency, only a few new antibiotics have been approved to address these infections. Although cannabinoids have been noted for their antibacterial properties, a comprehensive review of their effects on these bacteria has been lacking.
View Article and Find Full Text PDFProper counseling for diagnosis and management of cannabinoid hyperemesis syndrome: a case report.
Fam Pract
November 2024
Department of Family Medicine, McGill University, 5858 Chem. de la Côte-des-Neiges, Montréal, QC H3S 1Z1, Canada.
Background: Cannabinoid hyperemesis syndrome (CHS) is an increasingly recognized condition linked to chronic cannabis use, yet it remains frequently overlooked in clinical practice. The syndrome is characterized by cyclic episodes of severe nausea, vomiting, and abdominal pain, often relieved temporarily by hot showers or baths. With the rising prevalence of cannabis use following its legalization, the incidence of CHS has surged, presenting a significant challenge in both diagnosis and management within primary healthcare settings.
View Article and Find Full Text PDFCannabinoid hyperemesis syndrome: genetic susceptibility to toxic exposure.
Front Toxicol
October 2024
CReDO Science, Austin, TX, United States.
Cannabinoid hyperemesis syndrome presents as a complex of symptoms and signs encompassing nausea, vomiting, abdominal pain, and hot water bathing behavior, most typically in a heavy cannabis user. Its presentation is frequently associated with hypothalamic-pituitary-adrenal axis activation with stress and weight loss. Recent investigation has identified five statistically significant mutations in patients distinct from those of frequent cannabis users who lack the symptoms, affecting the TRPV1 receptor, two dopamine genes, the cytochrome P450 2C9 enzyme that metabolizes tetrahydrocannabinol, and the adenosine triphosphate-binding cassette transporter.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!